Biobanking in Atherosclerotic Disease, Opportunities and Pitfalls
2011

Biobanking in Atherosclerotic Disease: Opportunities and Pitfalls

Sample size: 1500 publication Evidence: moderate

Author Information

Author(s): Scholtes V.P.W, de Vries J.P.P.M, Catanzariti L.M, de Kleijn D.P.V, Moll F.L, de Borst G.J, Pasterkamp G

Primary Institution: University Medical Center Utrecht

Hypothesis

The study explores the role of biobanks in identifying biomarkers for cardiovascular diseases.

Conclusion

Biobanks are crucial for understanding atherosclerosis and developing predictive biomarkers, but challenges remain in their implementation and data management.

Supporting Evidence

  • Biobanks enable the study of genetic and environmental factors in diseases.
  • The Framingham Heart Study is a key example of a successful population-based biobank.
  • Biobanks can help identify biomarkers for predicting cardiovascular events.

Takeaway

Biobanks collect samples from people to help scientists find out what causes heart diseases and how to predict them better.

Methodology

The review discusses the historical context, advantages, and limitations of biobanks in cardiovascular research.

Potential Biases

Concerns about privacy and ownership of biological samples in biobanking.

Limitations

The study highlights the limitations of current biobank studies, including reliance on retrospective data and challenges in identifying vulnerable patients.

Participant Demographics

The study references a population-based biobank involving 28,000 citizens from Framingham, US.

Digital Object Identifier (DOI)

10.2174/157340311795677707

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication